Klotho
Anti-Aging / LongevityAlso known as: Alpha-Klotho, Soluble Klotho, Anti-Aging Protein
Mechanism
A protein discovered in 1997 with remarkable anti-aging effects — mice engineered to overproduce it live about 30% longer. The circulating form (soluble Klotho) acts as a hormone throughout the body, reducing oxidative stress and calming down the insulin/IGF-1 aging pathway. Klotho levels decline with age and kidney disease. Named after the Greek goddess who spins the thread of life.
Technical detail
Type I transmembrane protein (1,012 amino acids) primarily expressed in kidney distal tubules and brain choroid plexus. The extracellular domain is shed by ADAM10/17 secretases, generating circulating soluble Klotho (sKlotho). Mechanisms: (1) Co-receptor for FGF23 — forms complex with FGFR1c to enable FGF23 signaling for phosphate/vitamin D homeostasis. (2) Inhibits insulin/IGF-1 signaling (IIS) — suppresses PI3K/Akt, upregulating FOXO transcription factors and MnSOD (antioxidant). (3) Suppresses Wnt signaling — binds Wnt ligands, reducing cellular senescence. (4) Inhibits TGF-beta1 signaling — anti-fibrotic. (5) Suppresses NF-kB — anti-inflammatory. Kuro-o et al. (1997) Nature: Klotho-deficient mice show premature aging phenotype. Kurosu et al. (2005) Science: overexpression extends lifespan ~30%. sKlotho declines ~50% between ages 40-80. Unity Biotechnology and others exploring Klotho-based therapeutics.
Effects
RENAL: Klotho was first identified in mice where its deletion caused severe premature aging including renal failure (Kuro-o et al., 1997, Nature). Functions as a co-receptor for FGF23 in the kidney, regulating phosphate homeostasis and vitamin D metabolism (RCT-level evidence for mechanism, established biochemistry). Klotho-deficient mice develop severe nephrocalcinosis. In CKD patients, circulating Klotho levels decline proportionally with disease severity (human observational, multiple studies). Protects renal tubular cells from oxidative stress and apoptosis (animal, in vitro). Attenuates renal fibrosis by suppressing TGF-β/Smad3 signaling (animal). CARDIOVASCULAR: Soluble Klotho (s-Klotho) protects against vascular calcification — inhibits phosphate-induced vascular smooth muscle cell transdifferentiation to osteoblast-like cells (in vitro, animal). Low serum Klotho is independently associated with cardiovascular mortality in CKD patients (human observational: Semba et al., 2011, JAMA). Reduces oxidative stress in endothelium. Suppresses endothelial inflammation via inhibition of NF-κB (in vitro). Protects against cardiac hypertrophy (animal). NEUROLOGICAL: Landmark finding: a single injection of Klotho protein fragment (KL-F) enhanced cognition in young and old mice within hours, lasting weeks (Dubal et al., 2014, Cell Reports). Klotho enhances NMDA receptor signaling and GluN2B subunit function (animal). Klotho KL-VS heterozygosity (gain-of-function variant) associated with higher IQ, larger brain volume, and better cognitive function in humans (human genetics: Dubal et al., 2014, Cell Reports). Protects against neurodegeneration in Alzheimer's models (animal). May enhance oligodendrocyte maturation and myelination (animal). ENDOCRINE: Co-receptor for FGF23 — regulates the FGF23/Klotho/Vitamin D axis that controls calcium and phosphate homeostasis (established biochemistry, RCT-equivalent evidence). Modulates insulin/IGF-1 signaling — Klotho overexpression extends lifespan partly through suppression of insulin/IGF-1 pathway (animal: Kurosu et al., 2005, Science). Influences parathyroid hormone regulation. IMMUNE: Suppresses NF-κB-mediated inflammation (in vitro, animal). Reduces TNF-α, IL-6, and IL-8 expression. Anti-fibrotic effects across multiple organs via TGF-β suppression. Modulates Wnt signaling (which drives cellular senescence when overactive). METABOLIC: Klotho-overexpressing mice have reduced adiposity and improved insulin sensitivity (animal). Involved in FGF21 signaling (metabolic regulator). Protects against oxidative stress via upregulation of MnSOD and catalase through FOXO transcription factor modulation (in vitro, animal). MUSCULOSKELETAL: Klotho influences calcium/phosphate balance critical for bone health. Klotho-deficient mice develop severe osteoporosis. May protect against sarcopenia via its effects on muscle stem cell function and oxidative stress (animal). SKIN: Klotho-deficient mice show severe skin atrophy. Protects dermal cells from oxidative damage. HEPATIC: Emerging data on hepatoprotective effects via anti-fibrotic and anti-inflammatory mechanisms (animal). GI: Limited direct data. REPRODUCTIVE: Klotho-deficient mice are infertile. Role in reproductive aging being explored. Tier 3: Practitioner protocols for exogenous Klotho are still very early-stage. Most clinical interest is in Klotho as a biomarker (serum s-Klotho levels) rather than a therapeutic. Case reports of Klotho peptide fragment administration in longevity clinics are emerging. The KL-VS genotype (gain-of-function) is increasingly tested in longevity panels.
Practitioner Guide
DOSING TIPS: VERY EARLY-STAGE for therapeutic administration. No established human dosing protocol. The Dubal lab (UCSF) used Klotho protein fragments (KL-F, the KL1 domain) in mice at 10 μg/kg single IV injection. Human-equivalent dosing is being explored in clinical trials (first-in-human trial initiated 2023 at UCSF). Some longevity practitioners are experimenting with Klotho protein fragments at extrapolated doses, but this is highly experimental. More established approach: optimize endogenous Klotho levels through lifestyle and supplementation. STRATEGIES TO RAISE ENDOGENOUS KLOTHO: Exercise — aerobic exercise increases circulating Klotho levels (human RCT: Matsubara et al., 2014). Vitamin D optimization — 25(OH)D levels of 40-60 ng/mL support Klotho expression. PPAR-γ agonists upregulate Klotho (mechanism: epigenetic derepression of the Klotho gene promoter). Reduce phosphate load — high dietary phosphate suppresses Klotho; limit processed food/soda with phosphate additives. ACE inhibitors and ARBs upregulate Klotho expression in the kidney (clinical data, human). Statins may upregulate Klotho (animal data). SUPPLEMENT SYNERGIES: Vitamin D3 (4000-5000 IU/day) + vitamin K2 (MK-7, 200 μg/day) — supports the Klotho/FGF23/vitamin D axis. Astragaloside IV — upregulates Klotho expression in animal models. Probiotics (Lactobacillus species) — gut microbiome influences Klotho expression (animal). Omega-3 fatty acids — anti-inflammatory support for Klotho signaling pathways. NAD+ precursors — may support Klotho expression through sirtuin activation. TIMING: If using exogenous Klotho peptide (experimental): morning administration based on mouse data showing rapid cognitive effects. Endogenous optimization: vitamin D with meals, exercise in morning/afternoon. CYCLING: No established cycling protocol for exogenous Klotho. Endogenous optimization strategies are continuous. STACKING: Longevity stack: Klotho optimization + Epithalon + NAD+ precursor + senolytics (sequential). Cognitive stack: Klotho + Semax + Selank + lion's mane. Renal protection: Klotho optimization + ACE inhibitor (prescription) + low-phosphate diet. CONTRAINDICATION NUANCES: Monitor calcium and phosphate levels — Klotho modulates the FGF23/phosphate axis. Excess Klotho activity could theoretically cause hypophosphatemia and impaired vitamin D activation. Patients with hypoparathyroidism or hypophosphatemia should avoid exogenous Klotho. Unknown interactions with CKD medications that affect phosphate metabolism. STORAGE: Klotho protein fragments — store at -80°C for long-term, -20°C for short-term. Extremely fragile protein — degrades rapidly at room temperature. Reconstituted solutions: use immediately or within hours. PATIENT EDUCATION: Klotho is one of the most promising longevity targets. Named after the Greek Fate who spins the thread of life. The KL-VS genotype finding (that a natural Klotho variant increases IQ and lifespan) is one of the most compelling discoveries in longevity genetics. For now, focus on lifestyle optimization to raise endogenous Klotho. Direct administration is coming but still experimental. Get serum Klotho measured as a baseline (Quest/Labcorp now offer it). The UCSF clinical trial is the key one to watch. Tier 4 community intelligence: Biohacking community is very excited about Klotho. Some early adopters report improved cognitive clarity from experimental Klotho peptide fragments, but placebo effect cannot be excluded given the very early stage. Genotyping for KL-VS (via 23andMe raw data or targeted test) is becoming popular in longevity circles.
Research Summary
TIER 1 (Gold Standard): Kuro-o et al., 1997 — discovery of Klotho: mutation causes premature aging in mice (Nature, PMID: 9363890). Dubal et al., 2014 — Klotho KL-VS variant associated with enhanced cognition and larger brain volume; KL-F injection enhanced cognition in mice (Cell Reports, PMID: 24882005). Kurosu et al., 2005 — Klotho suppresses insulin/IGF-1 signaling and extends lifespan (Science, PMID: 16123266). Semba et al., 2011 — low plasma Klotho associated with cardiovascular disease in community-dwelling adults (JAMA, PMID: 21189220). UCSF first-in-human Klotho trial initiated 2023 (NCT05632172). TIER 2 (Strong): Xu & Sun, 2015 — Klotho gene delivery for kidney disease (Gene Therapy, comprehensive review). Hu et al., 2011 — Klotho and vascular calcification (Kidney International). Leon et al., 2017 — Klotho as CKD biomarker (Clinical Chemistry). Examine.com: limited entry; DrugBank: not listed as drug. TIER 3 (Moderate): Clinical observations from nephrology practice — Klotho as prognostic biomarker in CKD. Conference presentations at American Society of Nephrology and Gerontological Society. Practitioner case series measuring s-Klotho levels before/after lifestyle interventions. International data: Japanese researchers (where Klotho was discovered) have extensive epidemiological data linking Klotho levels to aging outcomes. KEY FINDINGS: (1) Klotho is one of the most validated longevity genes — its discovery was a paradigm shift. (2) The cognitive enhancement finding (single injection improving cognition) could be transformative. (3) Renal protection is the most clinically developed application. (4) KL-VS genotype is a real-world example of beneficial Klotho variation. (5) First-in-human trial is underway. GAPS: Human dosing for exogenous Klotho. Delivery challenges (protein therapy, not small molecule). Duration of cognitive enhancement in humans. Whether s-Klotho levels can be reliably raised by lifestyle alone. Long-term effects of Klotho supplementation. ACTIVE TRIALS: NCT05632172 — UCSF Phase 1 trial of recombinant Klotho protein in healthy adults (first-in-human). Multiple observational studies tracking Klotho as a biomarker in CKD and cardiovascular disease.